BCX4208
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background Most gout patients treated with 300 mg/d allopurinol do not reach the therapeutic goal range serum uric acid…
Background BCX4208, a novel purine nucleoside phosphorylase inhibitor, blocks uric acid production at a step preceding xanthine…
Background Common comorbidities associated with gout, including obesity, hypertension, diabetes, and chronic kidney disease, may…
Background BCX4208 is an oral, once-daily, purine nucleoside phosphorylase (PNP) inhibitor in clinical development as add-on…